Physician profile
Jamie E Crain
NPI 1104302637
$2,323.33
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,301 · 2022: $22.62.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $365.77 | 2021-2022 | |
| Esperion Therapeutics, INC. | $346.99 | 2021 | |
| Clarus Therapeutics INC. | $242.00 | 2021 | |
| Amarin Pharma, INC. | $226.73 | 2021 | |
| Corcept Therapeutics | $212.91 | 2021 | |
| Recordati_rare_diseases_inc. | $194.62 | 2021 | |
| Novo Nordisk INC | $191.09 | 2021 | |
| Abbvie INC. | $82.19 | 2021 | |
| Merck Sharp & Dohme LLC | $74.62 | 2021 | |
| Insulet Corporation | $72.11 | 2021 | |
| Antares Pharma, INC. | $55.53 | 2021 | |
| Mannkind Corporation | $45.71 | 2021 | |
| Ibsa Pharma INC. | $40.35 | 2021 | |
| Dexcom, INC. | $36.10 | 2021 | |
| Ascensia Diabetes Care US INC. | $32.11 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $30.56 | 2021 | |
| Sanofi-Aventis U.S. LLC | $27.52 | 2021 | |
| Zealand Pharma US, INC. | $18.48 | 2021 | |
| Amryt Pharma Holdings LTD | $14.12 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.82 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Crain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.